Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSummaCare Gene Therapy Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentSummaCarePolicy N/A

    Gene Therapy Policy

    Customize your policy alerts

    Sign up for all summacare policy alerts

    Know when summacare releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical coverage review and precertification for gene therapy, including non-CAR-T and CAR-T therapy, for commercial and Medicare members.

    Policy Summary
    PayerSummaCare
    PolicyGene Therapy Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateNot specified
    Key ActionObtain precertification for all gene therapy before treatment, and obtain prior approval for inpatient or out-of-network care.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    AllGene therapy services requiring precertification
    6FDA-approved gene therapy disease areas listed
    7 daysMinimum CAR-T post-infusion monitoring
    2 hoursCAR-T travel limit after infusion
    2Plan types covered

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Gene Therapy Coverage Criteria

    General Gene Therapy Authorization

    Gene therapy requests are reviewed on a case-by-case basis and require precertification.

    General gene therapy authorization: The request is for gene therapy, and required precertification has been obtained before treatment.

    Precertification is required for all gene therapy. The policy does not provide a single universal clinical-eligibility checklist.

    Non-CAR-T Gene Therapy

    Non-CAR-T gene therapy requests are evaluated individually.

    Non-CAR-T therapy review: The request concerns a non-CAR-T gene therapy and is reviewed by SummaCare when it is non-oncology-related or otherwise not assigned to EviCore.

    The policy lists FDA-approved gene therapy disease areas, including Hemophilia B, melanoma, retinal dystrophy, childhood cerebral adrenoleukodystrophy (X-linked), spinal muscular atrophy, and beta thalassemia; listing alone does not guarantee coverage.

    CAR-T Gene Therapy

    CAR-T and cancer-related gene therapy requests follow the designated review pathway.

    CAR-T review and post-treatment requirements: CAR-T therapy is reviewed by EviCore. Inpatient, out-of-network, and post-care components are reviewed through SummaCare Utilization Management and the Medical Director; Contracting is involved for out-of-network facilities. After infusion, the member is monitored for at least seven days and remains within a two-hour drive for four weeks.At least 7 days of monitoring; within a 2-hour drive for 4 weeks

    These operational requirements are stated in the policy for CAR-T therapy.

    Authorization and Precertification Requirements

    Prior Authorization

    Obtain precertification for all gene therapy

    Precertification is required for all gene therapy. Use SummaCare.com to access the complete list of gene therapy drugs and the precertification process.

    Prior Authorization

    Secure approval before inpatient or out-of-network care

    All inpatient and out-of-network gene therapy requests must be authorized before treatment or admission. Approval is required before any inpatient admission or out-of-network request.

    Denial Risk

    Missing authorization may result in denial

    Gene Therapy Overview

    Gene therapy is designed to treat disease by modifying a defective gene or replacing a missing or defective gene with a more functional version. Genetic material may be delivered directly into a patient's cells through an in-vivo vector or introduced into cells outside the body through an ex-vivo vector, after which the modified cells are administered to the patient. Treatment plans may include laboratory work, inpatient or outpatient care, and post-treatment monitoring. CAR-T therapy is a form of gene therapy in which a patient's T cells are genetically modified in the laboratory to express a chimeric antigen receptor that targets cancer cells.

    Gene Therapy Terms

    Non-CAR-T gene therapy
    DefinitionA treatment that introduces genetic material into cells.
    Genome editingUses molecular tools to change the existing DNA in a cell to treat or prevent disease.
    Typical settingGiven primarily in an outpatient setting; inpatient requests require prior authorization.
    CAR-T gene therapy
    DefinitionA treatment in which a patient's T cells are changed in the laboratory so they will attack cancer cells.
    Cell collectionT cells are collected from the member's blood through leukapheresis.
    Laboratory modification

    Gene Therapy Site-of-Care Requirements

    Billing Rule

    Use outpatient care for non-CAR-T therapy

    Non-CAR-T gene therapy is given primarily in an outpatient setting. Inpatient requests require prior authorization.

    Prior Authorization

    Authorize inpatient gene therapy admission in advance

    Approval is required before any inpatient admission for gene therapy. Obtain authorization before admitting the member for gene therapy treatment.

    Prior Authorization

    Authorize out-of-network treatment and confirm contracting

    Out-of-network gene therapy requests require prior authorization. Out-of-network facilities may also require Contracting involvement for CAR-T therapy.

    Policy Summary
    PayerSummaCare
    PolicyGene Therapy Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOct 8, 2026
    Last ReviewOct 8, 2026
    Next Review DateNot specified
    Key ActionObtain precertification for all gene therapy before treatment, and obtain prior approval for inpatient or out-of-network care.
    SourceLink
    On This Page
    Gene Therapy Coverage CriteriaAuthorization and Precertification RequirementsGene Therapy OverviewGene Therapy TermsGene Therapy Site-of-Care Requirements

    Gene therapy provided without required precertification may be denied, including an inpatient admission or out-of-network request without prior approval.

    A gene for a chimeric antigen receptor (CAR) is added to the T cells; large numbers of CAR-T cells are then manufactured in the laboratory over several weeks.
    Preparation and infusionChemotherapy is given several days before CAR-T infusion.
    Post-infusion monitoringMembers are monitored for at least 7 days after infusion and must remain within a 2-hour drive for 4 weeks after infusion.
    Ex-vivo vector
    DefinitionA delivery method in which genetic material is introduced into cells outside the patient's body.
    Cell handlingThe cells are modified outside the body before treatment.
    AdministrationThe modified cells are subsequently administered to the patient.
    In-vivo vector
    DefinitionA delivery method in which genetic material is introduced directly into cells within the patient's body.
    Delivery locationGenetic material is delivered inside the patient's body rather than into cells outside the body.
    PurposeThe delivered genetic material is used to modify or replace a defective or missing gene in the patient's cells.